Compare · regulatory status only
BPC-157 vs TB-500: legal status compared
The short answer
Legally, they are near-twins right now. Neither is FDA-approved or on the 503A list, so pharmacies are not authorized to compound either. Both were recommended for that list by the FDA's advisory committee on July 23, 2026 - each by an 8-6 vote with one abstention, each over the objection of FDA reviewers - and both recommendations await FDA action that has not begun. Both are prohibited in tested sport. The differences live in the details: what the FDA's reviewers objected to, and how each is captured by anti-doping rules.
Status comparison, not advice - Peptlas compares legality and oversight, never effects. Published Aug 27, 2026 (ET) · sources below
Side by side
| BPC-157 | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| FDA approval | None | None |
| On the 503A list (compoundable) | No | No |
| July 2026 PCAC vote | Recommended, 8-6 with 1 abstention | Recommended, 8-6 with 1 abstention |
| FDA reviewers' position | Against listing - characterization, immunogenicity, and efficacy concerns | Against listing - reviewers could not identify a single human clinical study |
| Sport (WADA) | Prohibited at all times under S0 (non-approved substances); USADA has warned athletes by name | Prohibited at all times as a growth factor / non-approved substance |
| Australia (TGA) | Schedule 4 (prescription-only) | Thymosin beta-4 treated as Schedule 4 |
| What changes next | FDA rulemaking, if the agency accepts the recommendation - 12-24 months, not started | Same - and neither recommendation obliges the FDA to act |
Identical votes, different objections
Both peptides cleared the committee on July 23, 2026 by the same margin - 8 to 6, one abstention, with free base and acetate forms voted separately - and in both cases the committee overrode the FDA's own scientific staff. But the staff objections differed in kind: for BPC-157, reviewers cited characterization, immunogenicity, and efficacy grounds; for TB-500, they reported something starker - they could not identify a single human clinical study of the substance. If the FDA weighs its own reviews when deciding whether to act on the recommendations, that difference may matter.
Until the agency does act, the practical answer for both is identical: an advisory vote changes nothing by itself, compounding remains unauthorized, and what is sold today is gray-market product under research-use-only labels. Both entries update within 24 hours of any official move, and the expected path - proposed rule, comment period, final rule - is a 12-to-24-month process the FDA has not begun for either.
Asked and answered
- Is BPC-157 or TB-500 legal to buy right now?
- Neither is an approved drug, and neither may be compounded by pharmacies. Neither is a federally scheduled controlled substance either. What is sold today is unapproved research-chemical product; the per-compound pages track the precise, sourced status of each.
- Did the FDA approve BPC-157 and TB-500 in July 2026?
- No. An advisory committee recommended both for the 503A compounding list, each 8-6 with one abstention. The votes are advisory, the FDA has not acted on them, and no legal status changed.
- Are BPC-157 and TB-500 banned for athletes?
- Yes, both - at all times. BPC-157 is captured by WADA's S0 category for non-approved substances and has been the subject of an explicit USADA warning; TB-500 is prohibited as a growth factor / non-approved substance.
Sources
- Healio - reported vote tallies, July 2026 PCAC
- FDA - PCAC July 2026: questions put to the committee
- FDA - PCAC briefing document, BPC-157 (July 2026 meeting)
- USADA - BPC-157 prohibited for athletes
- BSCG - TB-500 status in sport
- Mintz - FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do
Keep going
Get alerted when any status changes
One short, human-verified email whenever an official status changes. No spam, no selling.